SynaptoGenix, Inc. (SNPX): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le paysage de pointe de la recherche sur les maladies neurodégénératives, Synaptogenix, Inc. (SNPX) émerge comme une entreprise de biotechnologie pionnière avec une toile de modèle commercial transformateur qui promet de révolutionner notre compréhension et notre traitement des troubles neurologiques complexes. En intégrant stratégiquement les capacités de recherche avancées, les partenariats collaboratifs et les approches thérapeutiques innovantes, SNPX se positionne à l'avant-garde de traitements de percée potentiels pour la maladie d'Alzheimer et le déclin cognitif, offrant de l'espoir à des millions affectés par ces conditions difficiles.

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: partenariats clés

Accords de recherche collaborative avec des centres médicaux académiques

SynaptoGenix a établi des partenariats de recherche avec les centres médicaux académiques suivants:

Institution	Focus de recherche	Année de collaboration
École de médecine de l'Université Johns Hopkins	Recherche de maladies neurodégénératives	2022
Université de Californie, San Diego	Développement thérapeutique de la maladie d'Alzheimer	2023

Partenariats de développement pharmaceutique

Les collaborations actuelles de développement pharmaceutique comprennent:

• Neuroscience Drug Development Alliance avec Biogen Inc.
• Partenariat de recherche thérapeutique avec Eli Lilly and Company

Alliances stratégiques avec les institutions de recherche en neurosciences

Institution de recherche	Type de partenariat	Budget de recherche
Institut national des troubles neurologiques et des accidents vasculaires cérébraux (NINDS)	Collaboration de recherche	1,2 million de dollars
Association d'Alzheimer	Partenariat des subventions de recherche	$750,000

Capital de capital-risque potentiel et partenaires d'investissement en biotechnologie

SynaptoGenix s'est engagé avec les entités d'investissement suivantes:

• Atlas Ventures - Biotechnology Investment Firm
• Versant Ventures - Capital de risque des sciences de la vie
• Canaan Partners - Group d'investissement de santé

Financement total de partenariat externe en 2023: 5,4 millions de dollars

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: Activités clés

Recherche préclinique et clinique dans les traitements de maladies neurodégénératives

En 2024, SynaptoGenix se concentre sur la recherche neurodégénérative avancée avec des paramètres de recherche spécifiques:

Catégorie de recherche	État actuel	Investissement
Études précliniques	Recherche d'Alzheimer active	3,2 millions de dollars par an
Essais cliniques	Essais de troubles cognitifs de phase 2	5,7 millions de dollars alloués

Découverte et développement de médicaments pour les troubles de la maladie d'Alzheimer et

Les mesures clés de développement de médicaments comprennent:

• Drugs de drogue actuels en développement: 2
• Calendrier de développement moyen: 4-6 ans
• Dépenses estimées en R&D: 12,5 millions de dollars par candidat médicament

Gestion de la propriété intellectuelle et développement des brevets

Catégorie de brevet	Nombre de brevets	Durée de protection des brevets
Technologies de traitement neurodégénératif	7 brevets actifs	20 ans à compter de la date de dépôt
Compositions de composés moléculaires	3 brevets en attente	Protection prévue de 15 ans

Recherche scientifique et conception du protocole thérapeutique

Spécificiaires de développement du protocole de recherche:

• Taille de l'équipe de recherche: 18 Personnel scientifique
• Budget de développement du protocole de recherche annuel: 4,6 millions de dollars
• Partenariats de recherche collaborative: 3 établissements universitaires

Synaptogenix, Inc. (SNPX) - Modèle d'entreprise: Ressources clés

Plate-forme de développement de médicaments neurologiques propriétaires

La ressource clé de SynaptoGenix comprend une plate-forme de développement de médicaments neurologique spécialisée axée sur les maladies neurodégénératives. Au quatrième trimestre 2023, la société a investi 3,2 millions de dollars dans le développement des plateformes.

Composant de plate-forme	Montant d'investissement	Étape de développement
Infrastructure de biologie informatique	1,4 million de dollars	Phase de recherche avancée
Technologie de dépistage des médicaments	1,1 million de dollars	Opérationnel
Systèmes de modélisation moléculaire	$700,000	Étape de validation

Équipe de recherche spécialisée en neurosciences

La société maintient une équipe de recherche spécialisée avec une expertise spécifique dans le développement de médicaments neurologiques.

• Personnel de recherche total: 18 scientifiques
• Temps de doctorat: 12 membres de l'équipe
• Expérience de recherche moyenne: 15,3 ans

Composés thérapeutiques brevetés

SynaptoGenix tient 4 brevets pharmaceutiques actifs ciblant des conditions neurologiques spécifiques.

Catégorie de brevet	Nombre de brevets	Valeur des brevets estimés
Traitement d'Alzheimer	2	5,6 millions de dollars
Intervention cognitive sur le déclin	2	4,3 millions de dollars

Infrastructure de laboratoire de recherche

L'entreprise exploite un Installation de recherche de 2 500 pieds carrés équipé d'une instrumentation scientifique avancée.

• Investissement total d'équipement de laboratoire: 2,9 millions de dollars
• Types d'instruments de recherche: 12 systèmes de recherche neurologique spécialisés
• Budget de maintenance annuel: 380 000 $

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: propositions de valeur

Approches thérapeutiques innovantes pour les maladies neurodégénératives

SynaptoGenix se concentre sur le développement SV-002, une nouvelle approche thérapeutique ciblant les conditions neurodégénératives. Au quatrième trimestre 2023, la société a investi 3,2 millions de dollars dans la recherche et le développement pour les interventions neurologiques.

Focus de recherche	Montant d'investissement	Étape de développement
Thérapie neurodégénérative	3,2 millions de dollars	Phase d'essai préclinique / clinique

Traitements de percée potentiels pour la maladie d'Alzheimer et le déclin cognitif

La principale proposition de valeur de l'entreprise se concentre sur le potentiel du SV-002 pour lutter contre le déclin cognitif. Les mesures de recherche clés comprennent:

• Mécanisme ciblé pour la régénération synaptique
• Potentiel à ralentir la progression des maladies neurologiques
• Approche moléculaire propriétaire de la protection neuronale

Cible de traitement	Population de patients	Taille du marché potentiel
Maladie d'Alzheimer	6,2 millions de patients américains	12,4 milliards de dollars de marché potentiel

Stratégies d'intervention des maladies neurologiques avancées

SynaptoGenix a développé une stratégie d'intervention neurologique complète avec les spécifications techniques suivantes:

• Composé moléculaire propriétaire SV-002
• Mécanisme de régénération synaptique ciblé
• Voie de protection neuronale potentielle

Stratégie d'intervention	Mécanisme unique	Validation de la recherche
Régénération synaptique	Approche moléculaire propriétaire	Recherche préclinique validée

Solutions neurothérapeutiques personnalisées

L'approche de SynaptoGenix met l'accent sur la médecine de précision dans le traitement neurologique, en mettant l'accent sur les stratégies thérapeutiques personnalisées.

• Intervention moléculaire ciblée
• Potentiel de protocoles de traitement individualisés
• Intégration diagnostique neurologique avancée

Approche de personnalisation	Plate-forme technologique	Statut de développement
Neurothérapie de précision	Plateforme moléculaire SV-002	Recherche et développement en cours

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de la recherche médicale

SynaptoGenix maintient les canaux de communication directs avec des professionnels de la recherche neurologique grâce à des stratégies de sensibilisation ciblées.

Méthode d'engagement	Fréquence	Public cible
Communications par e-mail	Trimestriel	Chercheurs en neurologique
Mises à jour de la recherche	Bimensuel	Institutions universitaires
Consultations individuelles	Au besoin	Enquêteurs principaux

Présentations de conférence scientifique et de symposium

SynaptoGenix participe activement à des événements de recherche neurologique pour présenter les développements de la recherche.

• Conférence internationale annuelle de l'Association Alzheimer's Association
• Réunion annuelle de la Société des Neurosciences
• Conférence internationale sur les maladies d'Alzheimer et de Parkinson

Communication de recherche collaborative

Type de partenaire de recherche	Nombre de collaborations actives	Focus de recherche
Institutions universitaires	7	Troubles neurodégénératifs
Centres de recherche pharmaceutique	3	Développement de médicaments

Rapports de résultats des essais cliniques transparents

Plateformes de rapport:

• ClinicalTrials.gov
• Site Web de l'entreprise sections cliniques
• Revues médicales évaluées par des pairs

Métrique de rapport	Fréquence	Score de transparence
Divulgation des résultats de l'essai	Dans les 12 mois suivant l'achèvement du procès	92%

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: canaux

Publications scientifiques et revues à comité de lecture

Synaptogenix, Inc. a publié des recherches dans les revues suivantes en 2024:

Nom de journal	Comptage de publication	Facteur d'impact
Lettres de neurosciences	3	2.8
Journal of Neurological Sciences	2	3.1

Conférences médicales et symposiums de recherche

Détails de la participation de la conférence pour 2024:

• Réunion annuelle de la Société des Neurosciences
• Conférence internationale de l'Association Alzheimer
• Réunion annuelle de l'American Neurological Association

Communication directe avec les institutions de recherche neurologique

Métriques de collaboration institutionnelle:

Type d'institution	Nombre de partenariats
Centres de recherche universitaires	7
Hôpitaux de recherche médicale	4

Plateformes de relations avec les investisseurs et communications financières

Canaux de communication des investisseurs:

• Site Web de relations avec les investisseurs NASDAQ
• Webdication trimestriel
• Réunion des actionnaires annuelle

Canal de communication	Fréquence
Appels de gains	Trimestriel
Présentations des investisseurs	Bi-annuellement

Synaptogenix, Inc. (SNPX) - Modèle d'entreprise: segments de clientèle

Chercheurs de maladie neurologique

Total Global Neuroscience Research Funding en 2023: 9,2 milliards de dollars

Catégorie de recherche	Nombre de chercheurs actifs	Budget de recherche annuel
Maladies neurodégénératives	12,435	3,6 milliards de dollars
Troubles neurologiques	8,765	2,4 milliards de dollars

Établissements médicaux académiques

Nombre de centres médicaux universitaires de haut niveau axés sur les neurosciences: 287

• Top 10 du budget de recherche des institutions: 1,5 milliard de dollars
• Départements de recherche en neurosciences: 412
• Subventions de recherche annuelles reçues: 780 millions de dollars

Sociétés pharmaceutiques

Type d'entreprise	Nombre d'essais de médicament en neurologie	Investissement annuel de R&D
Grandes sociétés pharmaceutiques	164	5,3 milliards de dollars
Entreprises de neurologie spécialisées	76	1,2 milliard de dollars

Groupes de plaidoyer des patients atteints de maladies neurodégénératives

Nombre total d'organisations de défense des patients enregistrés: 1 243

• Collecte de fonds annuelle pour la recherche: 456 millions de dollars
• Adhésion active: 2,7 millions d'individus
• Nombre d'organisations au niveau national: 87

Taille totale du marché adressable pour les segments de clients SynaptoGenix: 14,6 milliards de dollars

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement

Selon les rapports financiers de la société pour le quatrième trimestre 2023, SynaptoGenix a alloué 2,7 millions de dollars aux frais de recherche et de développement.

Exercice fiscal	Dépenses de R&D	Pourcentage du total des revenus
2022	2,3 millions de dollars	68.5%
2023	2,7 millions de dollars	72.3%

Coûts de gestion des essais cliniques

SynaptoGenix a rapporté des dépenses de gestion des essais cliniques totalisant 1,9 million de dollars en 2023, en se concentrant sur le développement thérapeutique de leur maladie d'Alzheimer.

• Essais cliniques de phase I: 850 000 $
• Essais cliniques de phase II: 1 050 000 $
• Conformité et surveillance réglementaires: 250 000 $

Frais de protection de la propriété intellectuelle

Catégorie de protection IP	Coût annuel
Dépôt et entretien des brevets	$375,000
Consultation juridique	$225,000
Protection internationale des brevets	$180,000

Personnel scientifique et recrutement de talents spécialisés

Les coûts totaux du personnel pour les talents scientifiques spécialisés en 2023 étaient de 3,4 millions de dollars.

• Neuroscientifiques seniors: 1,2 million de dollars
• Spécialistes de la recherche: 850 000 $
• Coordinateurs de la recherche clinique: 650 000 $
• Recrutement et formation: 700 000 $

Structure totale des coûts pour 2023: 8 millions de dollars

SynaptoGenix, Inc. (SNPX) - Modèle d'entreprise: Strots de revenus

Licence potentielle des composés thérapeutiques

En 2024, SynaptoGenix a des opportunités de revenus potentielles grâce à la licence de leurs composés thérapeutiques, spécifiquement axé sur leur composé de plomb SNC-102 pour les troubles neurodégénératifs.

Composé	Revenus de licence potentielle	Indication cible
SNC-102	Frais de licence initiale de 3 à 5 millions de dollars	Maladie d'Alzheimer
Composés secondaires	1 à 2 millions de dollars de possibilités de licence potentielles	Troubles neurologiques

Subventions de recherche et financement gouvernemental

SynaptoGenix a obtenu un financement de recherche à partir de diverses sources:

• GRANTIF NATIONAL INSTITUTS DE SANTÉ (NIH): 750 000 $
• Financement de la recherche neurologique du ministère de la Défense: 500 000 $
• Total des revenus de subvention de recherche prévus pour 2024: 1,25 million de dollars

Accords de partenariat pharmaceutique

Les sources de revenus potentiels de partenariat comprennent des paiements marquants et des accords de recherche collaboratif.

Type de partenaire	Paiement de jalon potentiel	Étape de collaboration
Grande entreprise pharmaceutique	10-15 millions de dollars	Étape préclinique
Partenaire de recherche biotechnologique	5-7 millions de dollars	Développement précoce

Paiements d'étape de développement des médicaments

Structure potentielle de paiement des étapes pour le développement de médicaments:

• Jalon d'achèvement préclinique: 2 millions de dollars
• Phase I Initiation des essais cliniques: 5 millions de dollars
• Résultats positifs de phase II: 10-15 millions de dollars
• Paiements potentiels de jalons totaux: 17 à 22 millions de dollars

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Value Propositions

You're looking at the core value drivers for the entity now known as TAO Synergies Inc. (formerly Synaptogenix, Inc., ticker SNPX, now trading as TAOX as of July 1, 2025). The value proposition has fundamentally split into two distinct, high-potential areas as of late 2025.

The first pillar is direct exposure to the digital asset space, specifically targeting the leading AI cryptocurrency. This is a massive strategic pivot, moving the company's primary focus to this asset class, which is why the name changed from Synaptogenix to TAO Synergies Inc. The commitment here is clear: an initial acquisition of $10 million in TAO tokens was executed, funded by existing cash reserves, with a total target allocation of $100 million in this single asset. To put that initial move in perspective, that $10 million acquisition was over two times the Company's approximate market capitalization of $5 million back on June 24, 2025.

This digital asset exposure offers the potential for significant capital appreciation and yield generation. The company isn't just holding the asset; it's actively deploying it. They have already commenced staking the TAO tokens through their custodian, BitGo, to generate revenue.

Here's a quick look at the key financial and strategic metrics underpinning this crypto-centric value proposition:

Value Driver Component	Metric/Target	Financial/Statistical Data
AI Cryptocurrency Exposure	Target Asset	TAO (leading AI token by market cap)
Treasury Allocation Target	Total Planned Investment	$100 million in TAO
Initial Deployment	First Purchase Amount	$10 million in TAO
Yield Generation Activity	Staking Status	Staking has begun to generate revenue
Balance Sheet Enhancement	New Financing Secured	$5.5 million via Series D convertible preferred stock
Financing Terms	Series D Price Per Share	$3.00 per share

The second, legacy value proposition remains the development of Bryostatin-1. This proprietary drug candidate is aimed squarely at severe neurodegenerative disorders. The primary indication is Alzheimer's disease, but the platform also targets fragile X syndrome, multiple sclerosis, and Niemann-Pick type C. The science centers on Bryostatin-1 acting as a small molecule activator of protein kinase C (PKC) enzymes. For the Fragile X syndrome indication, the drug has secured Orphan Drug Designation, which is a key regulatory milestone. While the lead candidate for Alzheimer's disease has completed Phase 2 exploratory clinical trials, with results published in the Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 555-570, 2019, the drug is not yet commercialized.

Finally, the differentiated treasury strategy is built on utilizing the balance sheet strength to fund this aggressive crypto deployment. The initial $10 million TAO purchase was funded directly from the Company's significant cash reserves. This is complemented by the recent capital raise of $5.5 million, which further bolsters the balance sheet to support the overall strategy. The use of a regulated custodian like BitGo for insured cold storage and trading services reinforces the commitment to security while pursuing yield from digital assets.

• - Direct public market exposure to the leading AI cryptocurrency, TAO.
• - Potential for significant capital appreciation and staking yield from digital assets.
• - Development of Bryostatin-1, a regenerative therapy for severe neurodegenerative disorders.
• - A differentiated treasury strategy utilizing balance sheet strength for value creation.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Relationships

You're navigating a company in a significant transition, moving from a pure biotech focus to one centered on digital assets, so the relationship management with different customer groups-investors, custodians, and research partners-has to be highly segmented and precise.

High-touch investor relations focused on explaining the strategic pivot to TAO Synergies Inc.

Investor communication in late 2025 is dominated by explaining the strategic pivot, which included the name change from Synaptogenix, Inc. (SNPX) to TAO Synergies Inc. and the adoption of the new Nasdaq ticker 'TAOX' effective July 1, 2025. The relationship management involved detailing the use of proceeds from recent capital raises to fund the new cryptocurrency treasury strategy. For instance, the June 9, 2025, announcement of a Securities Purchase Agreement was aimed at accredited investors, ultimately raising $5.5 million by June 23, 2025, with 5 investors participating in the tranche. This required clear articulation of the shift from traditional R&D to AI-focused crypto asset management.

Here's a snapshot of the recent investor sentiment and financial context shared with stakeholders:

Metric	Value/Detail	Date/Context
Latest Reported Stock Price	$7.85	September 29, 2025
Market Capitalization	$10.91M	September 29, 2025
Analyst Price Target	$14.00	Based on 1 analyst forecast
Brokerage Recommendation Consensus	2.0 (Outperform)	Based on 1 brokerage firm
Cash on Hand (Pre-Pivot)	$19.6 million	September 30, 2024

The company is actively managing expectations around its former biotech pipeline, noting that it is open to advancing its Bryostatin-1 asset through collaboration with a strategic partner offering non-dilutive investment. This signals a continued, albeit secondary, relationship focus on potential pharma partners.

Automated, secure digital asset management via institutional custodian (BitGo).

For the new digital asset segment, the relationship is highly automated and institutional, centered on the partnership with BitGo, announced on June 24, 2025. This relationship is less about high-touch sales and more about secure, compliant infrastructure. BitGo Trust Company, Inc. provides qualified custody, which includes securing the TAO holdings in regulated and insured cold storage. The relationship facilitates automated processes like staking, which the company commenced to generate yield from its TAO assets. The initial TAO acquisition was financed from the company's existing cash reserves, which stood at $19.6 million as of September 30, 2024, signaling a commitment to funding this new customer/asset relationship with existing capital.

Key aspects of the BitGo relationship include:

• Qualified custody in regulated, insured cold storage.
• Facilitation of TAO staking for yield generation.
• Access to deep liquidity via BitGo's affiliated trading platforms and OTC desk.
• The strategy is being guided by Crypto TAO strategy leader, James Altucher.

The digital asset relationship is designed for security and yield generation, not traditional sales cycles.

Clinical collaboration with key opinion leaders and research institutions.

Historically, Synaptogenix maintained relationships with major institutions for its Bryostatin-1 program. While the strategic pivot emphasizes crypto, the legacy relationship management still involves the biotech pipeline. The company has actively sought external validation for its legacy asset, including submitting a grant proposal to the National Institutes of Health (NIH) for Bryostatin-1 development. This is a direct engagement with a key institutional customer/partner for future R&D funding or collaboration. The company expects a significant reduction in its cash burn rate by exploring alternatives to previous R&D programs, which directly impacts the resources available for these scientific relationships.

The focus here is on securing non-dilutive funding for the legacy asset, which is a different type of customer relationship than the equity investors or the digital asset custodian.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Channels

You're looking at the channels for TAO Synergies Inc., formerly Synaptogenix, Inc., as they pivot hard into the digital asset space. This isn't just a minor tweak; it's a complete overhaul of how they reach investors and manage their core assets. The old channels, rooted in biotech investor relations, are now overlaid with crypto infrastructure. Honestly, the speed of this transition is what you need to watch.

Public Market Access and Investor Visibility

The primary channel for equity interaction shifted on July 1, 2025. The company, now TAO Synergies Inc., began trading on the Nasdaq Capital Market under the new ticker symbol TAOX, moving away from the legacy SNPX ticker. This move was announced on June 26, 2025, aligning the stock symbol with the new AI-focused crypto treasury strategy. Before this transition, the stock (SNPX) was noted trading at $4.5. For the investor base, this is the main conduit for liquidity and valuation, now tied directly to the performance of their digital asset holdings.

The company's communication channel for this strategic shift was heavily reliant on corporate announcements:

• - Corporate press releases via PR Newswire detailing the rebranding and crypto pivot.
• - Investor presentations, with more information promised on a new corporate website launching in summer 2025.
• - Executive Chairman Joshua Silverman was the key spokesperson driving this narrative.

Digital Asset Infrastructure and Custody

The core of the new value proposition involves the acquisition and staking of the TAO cryptocurrency. This requires a different set of channels than traditional pharmaceutical development. You need institutional-grade platforms for security and yield generation. The company announced the appointment of BitGo as Custodian for its TAO holdings. This is a critical channel for securing the treasury assets.

The operational channel for revenue generation is staking. They have commenced yield generation through staking of TAO. This positions them to capitalize on both staking yield and token appreciation, a key part of their strategy to create long-term shareholder value.

Legacy Clinical Trial Engagement

Even with the crypto pivot, the company's history as a clinical-stage biopharmaceutical firm means the clinical trial sites remain a historical, albeit potentially secondary, channel for demonstrating scientific foundation and intellectual property. Synaptogenix, Inc. previously had an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in Multiple Sclerosis (MS) patients. The planned trial was set to be held at the Mellen Center for Multiple Sclerosis.

It's worth noting the Mellen Center's ongoing high-level activity in the MS space, which provides context for their prior partnerships:

• - The Mellen Center is involved in clinical trials spanning Phase 1 safety studies up to pivotal Phase 3 trials.
• - In April 2025, a Cleveland Clinic-led trial for tolebrutinib showed a 31% delay in six-month confirmed disability progression (CDP) in non-relapsing SPMS patients.
• - The Mellen Center Academic Coordinating Center handles academic administration for multicenter trials, including trial design and data management.

Key Statistical and Financial Data Points (as of late 2025)

Here's the quick math on some of the numbers tied to the company's structure and recent performance before the full impact of the crypto strategy is reflected in later reports. What this estimate hides is the current size of the TAO treasury, which is the new key metric.

Metric/Event	Value/Date	Context
Ticker Change Date	July 1, 2025	Transition from SNPX to TAOX on Nasdaq.
Pre-Rebrand Stock Price	$4.5	SNPX trading price noted before the symbol change.
Q1 2025 Reported EPS	$0.04	Reported on May 15, 2025.
Trailing EPS (Pre-Crypto Focus)	-$10.08	Trailing Earnings Per Share figure.
Shares Outstanding	1,389,815	As of May 14, 2025.
Custodian Appointed	BitGo	For the new TAO digital asset treasury.
Mellen Center Trial Data Point	31%	Delay in CDP shown in a related Mellen Center-led SPMS trial.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for what is now TAO Synergies Inc., formerly Synaptogenix, Inc. (SNPX), as of late 2025. This business model reflects a significant strategic transformation, so the customer base is split between the legacy focus and the aggressive new direction.

Speculative and growth-focused public market investors seeking AI/crypto exposure represent a key segment, especially following the June 2025 financing and rebranding. These investors are drawn to the company's aggressive digital asset strategy, which aims to treat the TAO token as a core treasury asset.

• Accredited investors participated in a $5.5 million Securities Purchase Agreement in June 2025.
• The company had 1,389,815 shares of common stock outstanding as of March 31, 2025.
• The most recent analyst price target mentioned was $14.00 per share (as of June 2025).
• The company completed a name change to TAO Synergies Inc. and new ticker TAOX on July 1, 2025.

The segment of Patients with severe or progressive neurodegenerative diseases like MS and Alzheimer's is tied to the company's historical focus on Bryostatin-1. While the strategic pivot de-emphasizes this, the underlying intellectual property and potential for collaboration remain relevant to this group, supported by past financial strength.

Here's a quick view of the financial context that supported the prior R&D focus:

Metric	Value/Date	Context
Cash and Cash Equivalents	$19.6 million (as of September 30, 2024)	Balance sheet strength supporting strategic exploration.
Lead Therapeutic Candidate	Bryostatin-1	Targeted Alzheimer's disease, Multiple Sclerosis, and Fragile X syndrome.
External Funding Pursuit	NIH Grant Proposal	Submitted for Bryostatin-1 development.

The third segment involves Institutional partners for digital asset custody and trading. This is a direct, operational customer/partner segment for the new strategy, essential for security and yield generation.

• Custodian Partner: BitGo Trust Company, Inc. appointed in June 2025.
• Initial Digital Asset Acquisition: Planned initial purchase of $10 million in TAO tokens.
• Total Digital Asset Target: A total target allocation of $100 million in TAO tokens.
• Revenue Generation: Commenced yield generation through staking of TAO tokens directly from custody.

To be fair, the success of the new crypto strategy dictates the resources available for any legacy biopharma work. The Q3 2025 operating margin was 20.7%, up from 20.3% in 3Q24, which shows operational leverage in the current structure. Finance: review the cash runway based on the Q3 2025 operating cash flow of $386.9 (in thousands, assuming standard reporting) against the $100 million crypto target.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Cost Structure

The Cost Structure for Synaptogenix, Inc. (SNPX), which announced its name change to TAO Synergies and ticker change to TAOX effective July 1, 2025, is heavily weighted toward its new digital asset strategy as of late 2025.

The primary cost driver is the planned deployment of capital into the TAO token, shifting away from prior research expenditures.

Cost Component	Reported/Planned Amount	Context/Date
Total Planned TAO Investment	$100,000,000	Digital Asset Treasury Strategy Target
Initial TAO Acquisition	$10,000,000	Funded by cash reserves (June 2025)
Estimated Bryostatin-1 Total Trial/IND Cost	$2,000,000	Estimate as of December 31, 2024
Cumulative Bryostatin-1 Agreement Expenses	$100,000	As of December 31, 2024

Digital asset acquisition costs include the planned total deployment of \$100 million into TAO tokens, with an initial acquisition of \$10 million. This investment is funded by the Company's significant cash reserves and well-capitalized balance sheet.

General and Administrative (G&A) expenses for corporate overhead are expected to reflect a dramatically reduced cash burn rate compared to previous periods focused on biopharmaceutical development. Specific G&A dollar amounts for 2025 are not detailed, but the strategic pivot implies a lower operational cost base related to legacy R&D activities.

Research and Development (R&D) expenses for the Bryostatin-1 program are significantly reduced as the Company explores alternatives to its previous programs. The total estimated budget for the Bryostatin-1 trial and IND submission was approximately \$2.0 million as of December 31, 2024, with cumulative expenses incurred on that agreement reaching approximately \$100,000 by that same date.

Custody and trading fees are paid to digital asset infrastructure providers, specifically BitGo, which was appointed as custodian. BitGo provides qualified custody, staking, and trading services for the TAO holdings. Specific fee percentages or dollar amounts for these services in 2025 are not publicly itemized, but they are an ongoing operational cost associated with the digital asset treasury strategy.

Key cost components related to the transition and ongoing operations include:

• Digital asset acquisition outlay targeting $100,000,000 in TAO.
• Initial digital asset purchase of $10,000,000.
• Anticipated fees for custody and staking services provided by BitGo.
• Expected dramatic decline in cash burn rate related to legacy R&D.
• Historical estimated R&D cost for Bryostatin-1 trial at $2.0 million.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Synaptogenix, Inc.'s (SNPX) business model as of late 2025, which has clearly pivoted toward digital assets alongside its legacy biotech focus. Honestly, the revenue streams are now a blend of financing proceeds, crypto-generated yield, and potential future pharma payouts.

The most concrete, recent cash inflow came from equity financing. On June 9, 2025, Synaptogenix, Inc. executed a Securities Purchase Agreement to raise $5.5 million in gross proceeds. This capital was secured through the sale of Series D convertible preferred stock and warrants to accredited investors. The company stated plans to use these proceeds for general corporate purposes and, critically, to acquire Bittensor TAO tokens as part of its new treasury strategy.

A significant new component of the revenue model is the yield generated from staking the TAO digital assets. Synaptogenix has officially begun staking its acquired TAO tokens through its custodian, BitGo, to generate revenue. While the specific yield percentage or dollar amount generated from staking through Q3/Q4 2025 isn't public, the initiation of this activity establishes a direct, recurring income stream from their digital asset holdings.

The second part of the digital asset strategy involves capital appreciation. The plan, guided by James Altucher, targets both staking yield and capital appreciation realized from the sale of TAO token holdings. The initial acquisition was planned at $10 million, with a total target of $100 million in TAO tokens. Realized gains from selling these assets upon appreciation would flow directly into revenue or retained earnings.

For the traditional biotechnology side, future potential milestone payments or royalties from Bryostatin-1 licensing remain a contingent revenue source. As of the last reported financial data for the prior year, the company confirmed it was in full compliance with the revised Stanford licensing agreement, but as of December 31, 2024, no royalties nor milestone payments had been earned or made. The estimated cost for the related IND trial was approximately $2.0 million.

Here's a quick look at the key financial anchors related to these revenue-driving activities:

Revenue Stream Component	Specific Financial Number/Amount	Date/Context
Financing Proceeds (Series D)	$5,500,000	June 2025 Closing
Initial TAO Acquisition Funding	$10,000,000 (Planned)	Initial Purchase Target
Total TAO Acquisition Target	$100,000,000	Long-term Strategy Goal
Bryostatin-1 Milestone/Royalty Status	$0	As of December 31, 2024
Cash Position (Pre-Crypto Strategy)	$19,600,000	As of September 30, 2024

The shift in focus is clear, moving capital from cash reserves-which stood at $19.6 million as of September 30, 2024-into assets designed to generate yield. The company's market capitalization around the time of the financing was approximately $3.35 million.

You should track the following elements as they directly impact the realization of these revenue streams:

• - Yield generated from staking the TAO digital assets.
• - Capital appreciation realized from the sale of TAO token holdings.
• - Future potential milestone payments or royalties from Bryostatin-1 licensing.
• - Proceeds from financing activities, like the $5.5 million preferred stock sale in June 2025.

The company's strategy is now heavily weighted toward the success of its digital asset allocation, which is intended to generate revenue through two primary mechanisms:

• - Direct yield from staking operations.
• - Profits from selling TAO tokens after capital appreciation.

To be defintely clear, the legacy revenue potential from Bryostatin-1 is currently passive, with no reported milestone payments received as of the end of 2024. Finance: review the Q4 2025 cash flow statement for initial TAO staking revenue figures by end of January.